Cystic Fibrosis Foundation distributed the following clinical trial updates during the month of July. Click the trial title to get more details.

Two alerts were issued on July 28, 2017:

Phase 2 study of VX-659 combination drug in adults with cystic fibrosis

Status: Enrolling

Description: This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the drug VX-659.

Age: 18 Years and Older

Mutation: No Mutation Requirement

Fev1% Predicted: 40% or greater

Number of Visits: 6

Length of Participation: 8 weeks

ClinicalTrials.gov link:https://clinicaltrials.gov/ct2/show/NCT03224351

Phase 1/2 study of VX-445 combination drug in healthy adults and then in people with cystic fibrosis

Status: Enrolling

Description: This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the drug VX-445.

Age: 18 Years and Older

Mutation: No Mutation Requirement

Fev1% Predicted: 40 to 90%

Number of Visits: 6

Length of Participation: 12 weeks

ClinicalTrials.gov link:https://clinicaltrials.gov/ct2/show/NCT03227471

One alert were issued on July 19, 2017:

RESULT: Study of liprotamase non-porcine enzymes

Status: Enrolling

Description: This randomized, parallel-assignment study is taking place at multiple care centers across the U.S. It will look at the effectiveness of liprotamase, a non-pig-derived pancreatic enzyme replacement therapy (PERT), as compared to a pig-derived PERT.

Age: 7 Years and Older

Mutation: No Mutation Requirement

Fev1% Predicted: No FEV1 Limit

Number of Visits: 17

Length of Participation: 30 weeks

ClinicalTrials.gov Link: https://www.clinicaltrials.gov/ct2/show/NCT03051490

Three alerts were issued on July 11, 2017:

Phase 1b study of inhaled AZD5634 in adults with CF

Status: Enrolling

Description: This study is taking place at multiple care centers across the US. It will look at the safety and tolerability of the inhaled drug AZD5634 and will use a placebo control.

Age: 18 Years to 60 Years

Mutation: No Mutation Requirement

Fev1% Predicted: 40% or greater

Number of Visits: 4

Length of Participation: 4 months

ClinicalTrials.gov Link: https://clinicaltrials.gov/ct2/show/NCT02950805

STOP: Standardized Treatment of Pulmonary Exacerbations Pilot Study

Status: Competed with results

Description: This study evaluated current physician treatment practices and patient outcomes for the management of pulmonary exacerbations (PEx). The goal was to collect this information so that it could later inform a future study of treatments of PEx.

Age: 12 Years and Older

Mutation: No Mutation Requirement

Fev1% Predicted: No FEV1 Limit

Number of Visits: 4

Length of Participation: 28 days

ClinicalTrials.gov Link: N/A

Study of in-line digestive enzyme cartridge (Relizorb) in people with CF who are currently receiving enteral tube feedings

Status: Competed with results

Description: This study looked at the safety and effectiveness of Relizorb®, a new digestive enzyme cartridge designed for people with pancreatic insufficiency (PI) that can be used in-line with enteral tube feeding. This cartridge delivers the digestive enzyme lipase, which helps the body digest fats contained in the tube-feeding formula.

Age: 4 Years to 82 Years

Mutation: No Mutation Requirement

Fev1% Predicted: Less than 100%

Number of Visits: 4

Length of Participation: 27 days

ClinicalTrials.gov Link:https://www.clinicaltrials.gov/ct2/show/NCT02598128